[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jiangsu Famous Medical Technology Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":153},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,61,89,112,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100602898","shenbai-granules-for-preventing-malignant-transformation-of-high-risk-colorectal-adenomas-100602898",false,"NCT07129499","Shenbai Granules for Preventing Malignant Transformation of High-risk Colorectal Adenomas","A Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Trial of Shenbai Granules for Preventing Malignant Transformation of High-Risk Colorectal Adenomas","Inclusion Criteria:\n\nAll of the following criteria must be met for enrolment:\n\n1. Aged 40-75 years, regardless of gender;\n2. High-quality colonoscopy performed within 14 days before randomisation, with initial endoscopic resection of all polyps and histological confirmation of at least one HR-CRA criteria;\n3. Complete endoscopic resection of every detected lesion;\n4. TCM syndrome differentiation of \"spleen deficiency with dampness-heat\";\n5. Signed informed consent and willingness to comply with long-term follow-up. a: High-quality colonoscopy criteria: Boston Bowel Preparation Scale score ≥ 6, cecal intubation confirmed by visualization of the ileocecal valve, and withdrawal time (excluding biopsy and polypectomy) ≥ 6 minutes.\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria will be excluded from the trial:\n\n1. Concomitant malignancy or history of malignancy in the digestive system;\n2. Personal or family history of familial adenomatous polyposis or hereditary non-polyposis colorectal cancer (Lynch syndrome);\n3. History of inflammatory bowel disease;\n4. Malignancy in any other organ system within 5 years before screening, except for adequately treated thyroid carcinoma, cervical carcinoma in situ, basal or squamous cell skin carcinoma, or ductal carcinoma in situ of the breast cured by radical surgery;\n5. Clinically significant organic disorders or neuro-psychiatric conditions that may affect treatment or prognosis, including but not limited to severe cardiovascular or cerebrovascular disease, autoimmune disease, motor, haematological, gastrointestinal, respiratory, immune, circulatory, reproductive, genitourinary, or endocrine disorders; coagulation abnormalities; or serious post-procedural complications (e.g., gastrointestinal bleeding, perforation, cholangitis, intra-abdominal infection, cardiorespiratory depression, mesenteric tear, or pneumoperitoneum), serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>2.5 × the upper limit of normal (ULN), or alkaline phosphatase (ALP) \\>2 × ULN;\n6. Active gastrointestinal disease, conditions predisposing to perforation, or disorders that could substantially interfere with the absorption, distribution, metabolism, or excretion of the investigational drug, such as inability to take oral medication, uncontrolled nausea or vomiting, intestinal obstruction, or chronic diarrhoea;\n7. Within 3 months before screening, continuous use for ≥3 months of ≥2 doses per week (with \\\u003C2-week interruption) of agents potentially protective against colorectal adenoma: NSAIDs (e.g., aspirin, ibuprofen, celecoxib), metformin, berberine hydrochloride, folic acid, vitamin D, selenium, calcium, systemic immunotherapy, or Chinese patent medicines or decoctions labelled for \"tonifying spleen and augmenting qi, clearing heat and eliminating dampness\". Subjects may be enrolled after a washout of 1 month or ≥5 drug half-lives, whichever is longer;\n8. Cold-pattern manifestations such as aversion to cold, cold pain in the waist\u002Fabdomen, cold extremities, or preference for hot drinks;\n9. Pregnant or lactating women, or men and women of child-bearing potential with plans to conceive during the trial or within 7 months after trial completion;\n10. Participation in another drug or device trial within 1 month or \\\u003C 5 half-lives of the investigational agent (whichever is longer) before screening, concurrent participation in another trial, or intention to participate in any other clinical trial during this trial;\n11. Known allergy or hypersensitivity to ≥ 2 drugs or foods, or hypersensitivity to any component of the trial medication;\n12. Any other condition that, in the opinion of the investigator, makes the subject unsuitable for enrolment (e.g., poor expected compliance, cognitive impairment).","ALL","40 Years","75 Years",{"count":20,"type":21},450,"ESTIMATED","INTERVENTIONAL",[24],"NA","This multicenter, randomized, double-blind, placebo-controlled trial will enroll 450 patients with completely resected high-risk colorectal adenoma (HR-CRA), randomly assigned (1:1) to 6 months of Shenbai Granules (SBG) or placebo, followed for 3 years post-polypectomy. Primary endpoint: 3-year cumulative incidence of metachronous HR-CRA. Secondary endpoints: incidence, number, size, distribution, histology of low-risk adenomas and serrated lesions, and colorectal cancer occurrence.",[27,28,29],"Colorectal Adenoma","High Risk","TCM","NOT_YET_RECRUITING","2025-08-11",{"date":33,"type":34},"2025-08-19","ACTUAL",{"date":36,"type":21},"2025-08-15",{"date":38,"type":21},"2028-11-30",{"name":40,"class":41},"Jiangsu Famous Medical Technology Co., Ltd.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":59,"leadSponsor":60,"locationsCount":42},"100602408","shenbai-granules-for-preventing-recurrence-of-low-risk-colorectal-adenomas-100602408","NCT07123116","Shenbai Granules for Preventing Recurrence of Low-Risk Colorectal Adenomas","Shenbai Granules for Preventing Recurrence of Low-Risk Colorectal Adenomas: A Multicenter Randomized Controlled Clinical Trial","Inclusion Criteria:\n\nTo be eligible for this study, all of the following inclusion criteria must be met:\n\n1. Aged 40-75 years, regardless of sex;\n2. Patients with histologically confirmed high-risk adenomas undergoing initial polypectomy, with high-quality colonoscopy performed within 14 days before randomization;\n3. Complete resection of all detected lesions during colonoscopy;\n4. Meeting TCM diagnostic criteria for spleen deficiency with dampness-heat syndrome;\n5. Provision of signed informed consent and ability to comply with long-term follow-up.\n\n   1. High-quality colonoscopy is defined as: Boston Bowel Preparation Scale (BBPS) score ≥6, cecal intubation with photo-documentation and withdrawal time ≥6 minutes. If quality standards cannot be confirmed, a repeat colonoscopy is required.\n\n      \\-\n\n      Exclusion Criteria:\n\n      Subjects who meet any of the following exclusion criteria will not be enrolled in this study:\n\n1\\) Complicated with malignant tumor or having a history of malignant tumor; 2) Personal or family history of familial polyposis or hereditary nonpolyposis colorectal cancer; 3) History of inflammatory bowel disease; 4) Suffering from malignant tumors of other systems except the study disease within 5 years before screening, except for malignant tumors that have been cured after treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or breast ductal carcinoma in situ treated with radical surgery); 5) Complicated with severe organic diseases such as cardiovascular and cerebrovascular diseases, autoimmune diseases, diseases of the motor, hematological, digestive, respiratory, immune, circulatory, reproductive, urinary, or endocrine systems, or patients with neuropsychiatric diseases, abnormal coagulation function, severe postoperative complications, such as gastrointestinal bleeding, perforation, cholangitis, abdominal infection, cardiopulmonary function depression, mesenteric laceration, or pneumoperitoneum, etc., or other acute and chronic diseases that may affect treatment and prognosis; those with Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) levels exceeding 2.5 times the upper limit of normal, Alkaline Phosphatase (ALP) levels exceeding 2 times the upper limit of normal, or abnormal electrocardiogram results assessed by investigators as clinically significant; 6) Patients with active gastrointestinal diseases, at risk of gastrointestinal perforation, or suffering from other diseases that can significantly interfere with the absorption, distribution, metabolism, or excretion of the trial drug, such as inability to take oral drugs, uncontrolled nausea or vomiting, intestinal obstruction, chronic diarrhea due to extensive intestinal resection, Crohn's disease, ulcerative colitis, or chronic diarrhea, etc.; 7) Having used the following treatments that may have a preventive effect on colorectal adenomas within 3 months before screening, for 3 consecutive months, at least 2 times a week, with an interruption time of less than 2 weeks: taking non-steroidal anti-inflammatory drugs such as aspirin, ibuprofen, celecoxib, etc, metformin, berberine hydrochloride, folic acid, vitamin D, selenium supplements, and calcium supplements, or maintaining systemic immunotherapy, or using Chinese patent medicines based on the indications in the instructions or Chinese herbal decoctions with the effects of invigorating spleen and replenishing qi, clearing heat and eliminating dampness; those who have undergone a washout period of 1 month or 5 half-lives of the drug whichever is longer can be enrolled; 8) Those with cold syndrome such as fear of cold, cold pain in the waist and abdomen, cold limbs, and preference for hot drinks when thirsty; 9) Pregnant or lactating women, as well as men or women of childbearing age who have plans for childbearing recently or within 7 months before the study; 10) Having participated in, or currently participating in, other clinical trials of drugs or research devices within 1 month before screening or within 5 half-lives of the trial drug whichever is longer, or planning to participate in any other clinical trials during this study; 11) Allergic constitution with a history of allergy to two or more drugs or foods or known allergy to the components of the study drug; 12) Other conditions deemed unsuitable for inclusion by the investigator, such as expected poor compliance, cognitive impairment, etc.\n\n\\-",{"count":20,"type":21},[24],"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shenbai Granules for Preventing Recurrence of Low-Risk Colorectal Adenomas（LRCRA）.\n\nStudy Population: Post-resection patients with low-risk colorectal adenomas and Spleen Deficiency with Dampness-Heat Syndrome per TCM criteria.\n\nSample Size: 450 subjects (1:1 randomization; 225 per arm) accounting for ≤20% dropout.\n\nStudy Hypothesis (Exploratory) ： This exploratory trial aims to evaluate the potential efficacy and safety of Shenbai Granules, a TCM formula, in reducing LRCRA recurrence. Based on preliminary data suggesting a 32.64% relative risk reduction in LRCRA recurrence at 2 years, we hypothesize that Shenbai Granules may demonstrate clinically meaningful prevention of adenoma recurrence and offer a favorable safety profile in the target TCM syndrome population. No formal statistical hypothesis is tested.\n\nStatistical Analysis Analysis Sets: mITT (primary efficacy), PPS, SS (safety). Primary Analysis: Proportion difference (Newcombe method) and χ²\u002FFisher's exact test (stratified CMH if applicable).\n\nSensitivity analyses: PPS, tipping-point imputation for missing data. Safety: Descriptive summaries of AEs\u002FSAEs (MedDRA-coded), lab abnormalities.",[27,29,54],"Low Risk","2025-08-08",{"date":57,"type":34},"2025-08-14",{"date":36,"type":21},{"date":38,"type":21},{"name":40,"class":41},{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":42},"100493753","phase-3-xian-lian-jie-du-optimization-decoction-as-an-adjuvant-treatment-for-prevention-of-recurrence-of-colon-cancer-100493753","NCT05709249","Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer","Efficacy of Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Stage IIIB\u002FIIIC Colon Cancer：a Study Protocol for a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Colon carcinoma confirmed by pathology.\\*\n\n   \\*Preoperative endoscopy showed that the distal end of the tumor was ≥12cm from the anal margin. If the patient did not undergo endoscopic examination before surgery, the distance of the tumor from the anal margin was ≥12cm according to the results of intraoperative examination or preoperative imaging examination.\n2. Completion of surgical resection of tumors with negative margins (R0 resection) and at least 3 months of adjuvant chemotherapy based on 5-fluorouracil (5-FU). \\*\n\n   \\*4 cycles of CAPOX (capecitabine and oxaliplatin), 6 cycles of FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or 4 cycles of single agent-5-FU, etc.\n3. Within 3 months after the completion of adjuvant chemotherapy.\n4. Patients with Stage IIIB or IIIC disease.\\*\n\n   \\*IIIB: T3-T4aN1\u002FN1cM0, T2-T3N2aM0 and T1-T2N2bM0, IIIC: T4aN2aM0, T3-T4aN2bM0 and T4bN1-N2M0, as defined by the American Joint Committee on Cancer (AJCC) 8th edition).\n5. Aged 20-80 years, men or women.\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n7. With no radiographic evidence of tumor recurrence.\n8. Sign the informed consent form.\n\nExclusion Criteria:\n\n1. Presence of other malignancies in the past 5 years except curatively treated basal cell carcinoma or cervical carcinoma in situ.\n2. Besides adjuvant chemotherapy, other adjuvant therapy such as radiotherapy, targeted therapy and immunotherapy has been used to treat colon cancer.\n3. Antitumor Chinese patent medicine and decoction have been used for more than 3 months after surgery or within 1 month before enrollment.\n4. Patients with severe comorbidities such as cardiovascular, cerebrovascular, renal, hepatic, hematopoietic system and other severe primary diseases.\n5. Allergic to the ingredients of XLJDOD.\n6. Any condition that is unstable or can jeopardize the safety of the patients and their compliance to the study, including pregnancy, plan to be pregnant, lactation and psychiatric disorders (schizophrenia, depression, and obsessive-compulsive disorder, etc.).\n7. Suspected or confirmed history of alcohol and drug abuse.\n8. Patients with other conditions considered by the investigator should not participate in the study.\n9. Patients who have recently participated in or are currently participating in other clinical trials of drugs.","20 Years","80 Years",{"count":71,"type":21},730,[73],"PHASE3","This study is designed as a multi-center, randomized, double-blind, placebo-controlled trial. Subjects in the intervention group will be treated with XLJDOD compound granule. Subjects in the control group will be treated with placebo (XLJDOD mimetic agent).",[76],"Colon Cancer",[78,79],"colon cancer","Traditional Chinese medicine","RECRUITING","2024-12-27",{"date":83,"type":34},"2024-12-30",{"date":85,"type":34},"2022-12-01",{"date":87,"type":21},"2028-04-01",{"name":40,"class":41},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":95,"minAge":96,"maxAge":18,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":4},"100563223","phase-4-an-exploratory-clinical-study-of-cdk46i-dalpiciclib-combined-with-ai-neoadjuvant-therapy-for-stage-ii-iii-hrher2--breast-cancer-100563223","NCT06613373","An Exploratory Clinical Study of CDK4\u002F6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+\u002FHER2- Breast Cancer","Inclusion Criteria:\n\n\\-\n\n1\\. For premenopausal or postmenopausal women, the definition of menopause:\n\n1. previous bilateral oophorectomy, or age ≥60 years; or\n2. Age \\\u003C60, natural postmenopausal status (defined as spontaneous cessation of regular menstruation for at least 12 consecutive months without other pathological or physiological causes), E2 and FSH at postmenopausal levels; 2. All patients had estrogen receptor (ER) positive (\\> 10%), HER2 receptor-negative invasive breast cancer regardless of PR expression level. Follow the 2018 ASC-CAP HER2 Negative Interpretation Guidelines. Immunohistochemical (IHC) scores of 0+ or 2+ and in situ hybridization (ISH) test negative were confirmed by pathology laboratory (HER-2\u002FCEP17 ratio \\\u003C 2.0); 3. Patients with initial treatment of stage II-III whose tumor stage meets AJCC 8th edition standard; 4. There is no known severe hypersensitivity to compounds or endocrine therapy similar to Darcilil or darcilil excipients.\n\n5\\. ECOG 0-1; 6. The patient must be able to swallow oral medications. 7. The functional level of the organ must meet the following requirements:\n\n1. Bone marrow function ANC ≥ 1.5×109\u002FL (no growth factor used within 14 days); PLT ≥ 100×109\u002FL (no corrective therapy used within 7 days); Hb ≥ 100 g\u002FL (no corrective therapy used within 7 days);\n2. Liver and kidney function TBIL≤1.5×ULN; ALT and AST≤3×ULN (ALT and AST≤5×ULN in patients with liver metastasis); BUN and Cr≤1.5×ULN and creatinine clearance ≥50 mL\u002Fmin (Cockcroft-Gault formula);\n3. 12-lead electrocardiogram QT interval ≤480 ms; 8. Able to accept all needle biopsies required by the protocol; 9. Voluntarily participate in this study, sign informed consent, have good compliance and be willing to cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Previously received any form of anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.);\n2. At the same time receive any anti-tumor treatment other than that prescribed in other protocols;\n3. Bilateral breast cancer, inflammatory breast cancer or ocessive breast cancer;\n4. Stage IV breast cancer;\n5. Other malignant tumors have appeared in the past 5 years;\n6. Severe heart, liver, kidney and other vital organ dysfunction;\n7. Inability to swallow, chronic diarrhea, and intestinal obstruction, with multiple factors affecting drug use and absorption;\n8. Known allergic history of the drug components of this protocol; Have a history of immunodeficiency, including HIV positive, HCV, active viral hepatitis B or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation;\n9. Pregnant and lactating women, fertile women who tested positive for baseline pregnancy tests, or women of childbearing age who were unwilling to take effective contraceptive measures during the entire test period;\n10. Concomitant diseases (including but not limited to severe high blood pressure, severe diabetes, active infection, etc.) that, in the judgment of the investigator, seriously endanger the patient's safety or affect the patient's ability to complete the study;\n11. Have a clear history of neurological or mental disorders, including epilepsy or dementia. The investigator did not consider the patient suitable for participation in any other condition of the study.","FEMALE","18 Years",{"count":98,"type":21},30,[100],"PHASE4","This is a single-arm, open-label, exploratory clinical study",[103],"Breast Cancer","2024-09-23",{"date":106,"type":34},"2024-09-25",{"date":108,"type":21},"2024-10-15",{"date":110,"type":21},"2026-10-30",{"name":40,"class":41},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":95,"minAge":96,"maxAge":18,"enrollmentInfo":119,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100557404","pyrotinib-combined-with-trastuzumab-subcutaneously-compared-intravenous-administration-in-the-treatment-of-her2-positive-early-breast-cancer-100557404","NCT06537674","Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer","An Exploratory Clinical Study of the PRO of Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer","Inclusion Criteria:\n\n1. Women aged ≥18 years and ≤75 years who are newly treated for breast cancer;\n2. Pathological examination confirmed HER2 positive (immunohistochemical staining ICH+++ or ICH++ and FISH positive);\n3. Patients with invasive breast cancer diagnosed histologically plus imaging as early (T1c-3, N0-1, M0) or locally advanced (T2-3, N2, or N3, M0);\n4. ECOG score 0-1;\n5. Plan to undergo the final surgical removal of breast cancer, i.e. breast-conserving surgery or total mastectomy, sentinel lymph node (SN) biopsy or axillary lymph node dissection (ALND);\n6. If the major organs function normally, the following criteria are met:\n\n(1) The standard of blood routine examination should meet: ANC ≥1.5×109\u002FL; PLT ≥90×109\u002FL; Hb ≥90g\u002FL; (2) Biochemical examination should meet the following criteria: TBIL≤ upper limit of normal value (ULN); ALT and AST≤1.5 times the upper limit of normal (ULN); Alkaline phosphatase ≤2.5 times the upper limit of normal (ULN); BUN and Cr≤1.5×ULN and creatinine clearance ≥50 mL\u002Fmin (Cockcroft-Gault formula); (3) Color Doppler ultrasonography and echocardiography: left ventricular ejection fraction (LVEF≥55%); (4) Fridericia calibrated QT interval (QTcF) for 18-lead ECG \\\u003C470 ms; 7. For female patients who are not menopausal or have not been surgically sterilized, they should consent to abstinence or use an effective contraceptive method during treatment and for at least 7 months after the last dose in the study treatment.\n\n8\\. Volunteer to join the study and sign the informed consent.\n\nExclusion Criteria:\n\n1. Known allergic history of the drug components of this protocol;\n2. Previously received antitumor therapy or radiation therapy for any malignant tumor (except for cured cervical carcinoma in situ and basal cell carcinoma);\n3. Has undergone major non-breast cancer related surgery within 4 weeks, or has not fully recovered from such surgery;\n4. Stage IV (metastatic) breast cancer patients;\n5. Inability to swallow, intestinal obstruction, or other factors affecting the administration and absorption of the drug;\n6. Serious heart disease or discomfort that cannot be treated;\n7. Suffering from mental illness or psychotropic substance abuse, unable to cooperate;\n8. Pregnant or lactating women;\n9. Patients with severe liver and kidney function diseases and blood system diseases;\n10. Those who were not considered suitable for inclusion by the researchers included: history of drug abuse, history of use of blood products, anticoagulant drugs and immunological drugs within the past year; Poor compliance and refusal to cooperate with treatment",{"count":120,"type":21},100,"OBSERVATIONAL","This study evaluated the clinical benefits of intravenous administration of pyrotinib combined with trastuzumab subcutaneous preparation by comparing the efficacy and quality of life of intravenous administration in the treatment of HER2-positive early breast cancer",[124],"HER2+ Breast Cancer","2024-08-01",{"date":127,"type":34},"2024-08-05",{"date":129,"type":21},"2024-08-15",{"date":131,"type":21},"2026-12-30",{"name":40,"class":41},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":96,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":4},"100526537","integrated-chinese-and-western-medicine-specialized-disease-cohort-for-colorectal-cancer-100526537","NCT06136026","Integrated Chinese and Western Medicine Specialized Disease Cohort for Colorectal Cancer","Integrative Chinese and Western Medicine for Colorectal Cancer: A Nationwide Prospective Cohort Study","Inclusion Criteria:\n\nCRC patients:\n\n1. The patient is over 18 years old;\n2. The patient meets the diagnostic criteria for colorectal cancer;\n3. The patient has not received anti-tumor treatment such as surgery, chemotherapy, radiotherapy, targeted therapy, or immunity in the past;\n4. The patient voluntarily participated in this study and signed an informed consent form.\n\nColorectal adenoma patients\n\n1. The patient is over 18 years old;\n2. The patient meets the diagnostic criteria for colorectal adenoma;\n3. The patient voluntarily participated in this study and signed an informed consent form.\n\nExclusion Criteria:\n\nCRC patients:\n\n1. Combined with other malignant tumors;\n2. The patient has severe cognitive impairment, dementia, and various mental disorders.\n\nColorectal adenoma patients:\n\n1. The patient had a history of malignancy;\n2. The patient has severe cognitive impairment, dementia, and various mental disorders.",{"count":141,"type":21},50000,"This is a nationwide cohort study on integrated traditional Chinese and Western medicine for colorectal cancer. The aim is to elucidate the distribution patterns of TCM syndromes in colorectal cancer and colorectal adenoma, reveal the relationship between TCM syndromes and diagnosis, prognosis, and prognosis. Based on biological samples, a phenotypic omics study of TCM syndromes in colorectal cancer and colorectal adenoma is conducted.",[144,27],"Colorectal Cancer","2023-11-15",{"date":147,"type":34},"2023-11-18",{"date":149,"type":21},"2023-12-01",{"date":151,"type":21},"2033-12-31",{"name":40,"class":41},""]